Daniel D. Burton - 07 Jun 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Issuer symbol
HCAT
Transactions as of
07 Jun 2021
Transactions value $
-$2,930,456
Form type
4
Filing time
09 Jun 2021, 21:17:00 UTC
Previous filing
07 Jun 2021
Next filing
03 Sep 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $561K +35.4K +12.52% $15.84 319K 07 Jun 2021 Direct
transaction HCAT Common Stock Sale -$597K -11.1K -3.49% $53.72* 308K 07 Jun 2021 Direct F1, F2
transaction HCAT Common Stock Sale -$163K -2.99K -0.97% $54.54* 305K 07 Jun 2021 Direct F1, F3
transaction HCAT Common Stock Sale -$2.15M -38.5K -12.63% $55.80* 266K 07 Jun 2021 Direct F1, F4
transaction HCAT Common Stock Sale -$586K -10.4K -3.92% $56.23* 256K 07 Jun 2021 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -35.4K -21.48% $0.00 130K 07 Jun 2021 Common Stock 35.4K $15.84 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 4, 2021, in accordance with Rule 10b5-1.
F2 Represents the weighted average sale price of the shares sold ranging from $53.08 to $54.07 per share, inclusive.
F3 Represents the weighted average sale price of the shares sold ranging from $54.10 to $55.04 per share, inclusive.
F4 Represents the weighted average sale price of the shares sold ranging from $55.14 to $56.13 per share, inclusive.
F5 Represents the weighted average sale price of the shares sold ranging from $56.14 to $56.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) though (5).
F6 25% of the 299,748 shares underlying the option vested in an annual installment on February 5, 2020 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.